Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2021 08:00 ET | Source: CinCor Pharma, Inc.

CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating CIN-107, a Selective Aldosterone Synthase Inhibitor, in Patients with Uncontrolled Hypertension and High Plasma Aldosterone

CINCINNATI, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), announced today the dosing of the first patient in its Phase 2 clinical trial evaluating CIN-107, a highly selective,...
October 20, 2020 08:00 ET | Source: CinCor Pharma, Inc.

CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects

CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that...
February 27, 2018 10:15 ET | Source: Marina Biotech, Inc.

Marina Biotech Announces a New Publication on Prestalia®

City of Industry, CA, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...
January 16, 2018 08:40 ET | Source: Marina Biotech, Inc.

Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio

City of Industry, CA, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...
November 27, 2017 08:30 ET | Source: Marina Biotech, Inc.

Marina Biotech Appoints Isaac Blech to its Board of Directors

City of Industry, CA , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics...